Want to see BNTC full AI Analyst Report?

Benitec Biopharma (BNTC) Price & Analysis

313 Followers

BNTC Stock Chart & Stats

$14.08

<$0.01(0.09%)

At close: Jan 08 4:00 PM EST

$14.08

<$0.01(0.09%)

Day’s Range― - ―

52-Week Range$9.85 - $16.76

Previous CloseN/A

Volume10.71K

Average Volume (3M)130.09K

Market Cap

$439.05M

Enterprise Value$341.96

Total Cash (Recent Filing)$184.76M

Total Debt (Recent Filing)$876.00K

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Sep 30, 2026

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.11

Shares Outstanding34,354,336

10 Day Avg. Volume82,163

30 Day Avg. Volume130,091

Financial Highlights & Ratios

PEG Ratio0.18

Price to Book (P/B)4.35

Price to Sales (P/S)0.00

P/FCF Ratio-17.95

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$25.00

Price Target Upside77.56% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.99

Revenue Forecast (FY)$27.32M

Bulls Say, Bears Say

Bulls Say

Low Leverage Balance SheetVery low debt relative to equity gives the company durable financial flexibility uncommon in early-stage biotech. This reduces near-term refinancing risk, supports sustained R&D spending through internal resources and asset liquidation options, and lengthens runway versus highly levered peers.

Proprietary DdRNAi PlatformA proprietary gene-silencing platform represents a structural competitive advantage: it can spawn multiple candidate programs, enable long-duration therapeutic effects, and attract partnerships or licensing. Platform ownership supports scalable long-term value creation if clinical validation succeeds.

Sizable Reported AssetsApproximately $187M of assets provides a tangible cushion and runway to fund clinical and preclinical work without immediate dilution. Combined with low leverage, sizeable assets support multi-quarter program advancement and strategic optionality for licensing or collaboration talks.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow of roughly -$20M TTM indicates the company must rely on external financing to continue operations. Over months this erodes runway, increases dilution risk, and can constrain program prioritization if capital markets tighten or partner deals lag.

Minimal Commercial Revenue Vs Large LossesWith essentially no recurring product revenue and nearly $49M net loss TTM, the business remains pre-commercial and heavily cost-driven. Lack of revenue undermines self-funding, delays break-even potential, and magnifies the impact of any development setbacks on long-term viability.

Equity Being Consumed (negative ROE)A TTM ROE near -39% signals persistent erosion of shareholder capital from operating deficits. Over a multi-month horizon this reflects that R&D spend is not yet converting to value, heightening pressure to secure funding and potentially prompting reprioritization or dilution that affects long-term investor returns.

Benitec Biopharma News

Guggenheim downgrades Benitec to Neutral, terminates coverage

Guggenheim downgraded Benitec Biopharma (BNTC) to Neutral from Buy without a price target while subsequently terminating coverage of...

1M ago

BNTC

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay downgraded Benitec Biopharma (BNTC) to Neutral from Buy with no price target Published first...

1M ago

BNTC

Benitec Biopharma Announces Board Changes and New Director

Benitec Biopharma ( ($BNTC) ) has provided an update. On May 22, 2026, Benitec Biopharma Inc.’s board appointed...

2M ago

BNTC

Benitec Biopharma: Buy Rating Reiterated on Promising BB-301 Data and Solid Cash Runway; $32 Price Target Maintained

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Benitec Biopharma and keeping the price target...

2M ago

BNTC

Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia

TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on...

2M ago

BNTC

Benitec Biopharma initiated with an Outperform at Evercore ISI

Evercore ISI initiated coverage of Benitec Biopharma (BNTC) with an Outperform rating and $25 price target BB-301 represents...

2M ago

BNTC

Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Benitec Biopharma and keeping the price target...

4M ago

BNTC

Benitec Biopharma announces interim Phase 1b/2a study of BB-301

Benitec Biopharma (BNTC) announced “promising” interim clinical results from the BB-301 Phase 1b/2a first-in-human study evaluating low dose...

4M ago

BNTC

Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on BNTC stock, giving a Buy rating on...

5M ago

BNTC

Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year

“We continue to be encouraged by the benign safety profile and the durability of efficacy demonstrated in our...

5M ago

BNTC

Benitec Biopharma files to sell 1.48M shares of common stock for holders

The company will not receive any of the proceeds from the sale of the common stock by the...

6M ago

BNTC

Benitec Biopharma first patient treated in Cohort 1 of BB-301 Phase 1b/2a study

Benitec Biopharma (BNTC) announced that the first patient treated in Cohort 1 of the BB-301 Phase 1b/2a clinical...

6M ago

BNTC

Benitec Biopharma Concludes 2025 Annual Stockholders Meeting

Benitec Biopharma ( ($BNTC) ) has shared an update. On December 1, 2025, Benitec Biopharma Inc. held its...

8M ago

BNTC

Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Benitec Biopharma (BNTC) to $32 from $35...

8M ago

BNTC

BNTC FAQ

What was Benitec Biopharma’s price range in the past 12 months?

Benitec Biopharma lowest stock price was $9.85 and its highest was $16.76 in the past 12 months.

What is Benitec Biopharma’s market cap?

Benitec Biopharma’s market cap is $439.05M.

When is Benitec Biopharma’s upcoming earnings report date?

Benitec Biopharma’s upcoming earnings report date is Sep 30, 2026 which is in 72 days.

How were Benitec Biopharma’s earnings last quarter?

Benitec Biopharma released its earnings results on May 14, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.268 by $0.028.

Is Benitec Biopharma overvalued?

According to Wall Street analysts Benitec Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Benitec Biopharma pay dividends?

Benitec Biopharma pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma dividends here

What is Benitec Biopharma’s EPS estimate?

Benitec Biopharma’s EPS estimate is -0.28.

How many shares outstanding does Benitec Biopharma have?

Benitec Biopharma has 34,354,336 shares outstanding.

What happened to Benitec Biopharma’s price movement after its last earnings report?

Benitec Biopharma reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.268. Following the earnings report the stock price went up 1.717%.

Which hedge fund is a major shareholder of Benitec Biopharma?

Currently, no hedge funds are holding shares in BNTC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Benitec Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.82%

Trailing 12-Months

Asset Growth

77.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Benitec Biopharma

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

Benitec Biopharma (BNTC) Earnings & Revenues

Historic Earnings Reports

BNTC Stock 12 Month Forecast

Average Price Target

$25.00

▲(77.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","15":"$15","21":"$21","27":"$27","33":"$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,15,21,27,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.69,14.175384615384615,15.66076923076923,17.146153846153844,18.63153846153846,20.11692307692308,21.60230769230769,23.087692307692308,24.573076923076925,26.05846153846154,27.543846153846154,29.02923076923077,30.514615384615382,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.69,13.636923076923077,14.583846153846153,15.53076923076923,16.47769230769231,17.424615384615386,18.371538461538464,19.318461538461538,20.265384615384615,21.212307692307693,22.159230769230767,23.106153846153845,24.053076923076922,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.69,13.098461538461539,13.506923076923076,13.915384615384616,14.323846153846153,14.732307692307693,15.14076923076923,15.54923076923077,15.957692307692307,16.366153846153846,16.774615384615384,17.183076923076925,17.591538461538462,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.775,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.36,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.47,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.97,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.69,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >